Durability questions remain, but Myval appears comparable to contemporary devices on the market, says Patrick Serruys.
A meta-analysis suggests adverse events are often falsely attributed to BP-lowering drugs, leaving patients undertreated.
The curves for TVF separated early and remained parallel in the complex cases, giving an advantage to the DCB group at 1 year ...
For stabilized patients undergoing complex PCI, left ventricular unloading with an Impella CP microaxial flow pump ...
Top-line results from the phase III trial show average weight losses of 19% to 28.3% by 80 weeks depending on dose.
The Bioadaptor coronary implant (Elixir Medical) continues to outperform contemporary drug-eluting stent technology over ...
Heart failure (HF) patients who have reduced or mildly reduced ejection fraction derive better outcomes when low-dose digoxin ...
There are still some kinks to be ironed out, including risks of hemolysis and valve thrombosis, to put things on par with ...
The data reflect a high degree of technical success, clinical efficacy, and safety of the new technique, says Gennaro ...
A meta-analysis confirms what’s known: physiology-guided PCI is “not a survival treatment” when compared with OMT.
Adverse pregnancy outcomes were linked to higher BP, BMI, and other cardiometabolic risk factors in kids 20 years later.
Baxdrostat (Baxfendy) has been approved by the US Food and Drug Administration for the treatment of patients with hypertension who have inadequately controlled blood pressure despite taking other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results